Nebenwirkungen · Aubagio
AUBAGIO 7 mg film-coated tablets AUBAGIO 14 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 14
HOS-126700 · Präparat HOS-096301
The following adverse reactions were more frequently reported in the paediatric population than in the adult population: • Alopecia was reported in 22.0% of patients treated with teriflunomide versus 12.3% in patients treated with placebo. • Infections were reported in 66.1% of patients treated with teriflunomide versus 45.6% in patients treated with placebo. Among them, nasopharyngitis and upper respiratory tract infections were more frequently reported with teriflunomide. • CPK increase was reported in 5.5% of patients treated with teriflunomide versus 0% in patients treated with placebo. The majority of the cases were associated with documented physical exercise. • Paraesthesia was reported in 11.0% of patients treated with teriflunomide versus 1.8% in patients treated with placebo. • Abdominal pain was reported in 11.0% of patients treated with teriflunomide versus 1.8% in patients treated with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T14:35:00Z · SHA-256 590c2a61b8e2e029ec7654e3780b1cba8a07adbbaa44e9523484198edf4cb160 · Passage 511056aa194befc3a3d0153c9bdc6e9196113cad879e375f62df19c7290d2dd7 · Zeichen 13403–14397 im Abschnitt